Published in FEBS Lett on February 15, 1988
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
The collagen-like component of the complement system, C1q, is recognized by 7 S autoantibodies and is functionally impaired in synovial fluids of patients with rheumatoid arthritis. Immunology (1996) 0.79
Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids. Clin Exp Immunol (2000) 0.77
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 8.20
Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum (1977) 3.23
HL-A antigens in sarcoidosis and rheumatoid arthritis. Lancet (1972) 1.84
Biosynthesis of the first component of complement by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1 subunits. J Immunol (1978) 1.79
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 1.75
Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol (1974) 1.69
Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation (2001) 1.64
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
A 66-kilodalton heat shock protein of Salmonella typhimurium is responsible for binding of the bacterium to intestinal mucus. Infect Immun (1992) 1.41
Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem (1996) 1.35
Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol (2000) 1.25
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 1.23
[Measurement of complement with a microliter method]. Z Med Mikrobiol Immunol (1969) 1.22
Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry (1976) 1.20
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--I. Effect on fluid phase C1 and on C1 bound to EA or to EAC4. Immunochemistry (1976) 1.20
Studies on antigen-induced arthritis in mice. III. Cell and serum transfer experiments. J Immunol (1977) 1.18
Interactions between mycoplasma pneumoniae and the first components of complement. Infect Immun (1977) 1.17
HL-A antigens of patients with sarcoidosis. Tissue Antigens (1974) 1.15
Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med (1987) 1.14
Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol (2001) 1.14
Inflammation in areas of remote changes following focal brain lesion. Prog Neurobiol (2005) 1.11
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer (2010) 1.11
Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J Immunol (2000) 1.11
vacA genotypes and genetic diversity in clinical isolates of Helicobacter pylori. Clin Diagn Lab Immunol (1998) 1.10
Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry (1976) 1.07
Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Antibody-independent killing of gram-negative bacteria via the classical pathway of complement. Immunol Lett (1987) 1.03
Studies on antigen-induced arthritis in mice. II. Immunologic correlates of arthritis susceptibility in mice. J Immunol (1977) 1.03
Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J Neurol Sci (1995) 0.99
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int (1988) 0.97
Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota. Curr Top Microbiol Immunol (1985) 0.97
In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015). Eur J Cancer Clin Oncol (1987) 0.97
Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol (1983) 0.95
Interaction of purified lipoteichoic acid with the classical complement pathway. Infect Immun (1986) 0.94
The role of accessory cells in polyclonal T cell activation. I. Both induction of interleukin 2 production and of interleukin 2 responsiveness by concanavalin A are accessory cell dependent. Eur J Immunol (1983) 0.94
Proteinase inhibitors in rheumatoid arthritis. Ann Rheum Dis (1975) 0.94
Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria. Infect Immun (1982) 0.93
High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav (2012) 0.93
Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J Immunol (1982) 0.92
Strain specificity and cholinergic modulation of visuospatial attention in three inbred mouse strains. Genes Brain Behav (2006) 0.92
IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol (2000) 0.91
Activation of the first component of complement evidence for an internal activation step. J Immunol (1972) 0.91
The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes. Prog Allergy (1982) 0.89
Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol (1996) 0.89
The role of the classical pathway for the bactericidal effect of normal sera against gram-negative bacteria. Curr Top Microbiol Immunol (1985) 0.89
Ultracentrifugation studies on the native form of the first component of human complement (C1). FEBS Lett (1976) 0.89
Granulocyte elastase as a new biochemical marker in the diagnosis of chronic joint diseases. Rheumatol Int (1986) 0.88
The first component of complement in serum: evidence for a hitherto unrecognized factor in C1 necessary for internal activation. J Immunol (1973) 0.88
The functions of endogenous C1q, a subcomponent of the first component of complement, as a receptor on the membrane of macrophages. Mol Immunol (1982) 0.88
Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. J Immunol (1991) 0.88
Clinical and immunological studies in a case of selective complete C1q deficiency. Clin Exp Immunol (1979) 0.88
Alpha-1 antitrypsin phenotypes in rheumatoid arthritis. Lancet (1977) 0.87
Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett (2001) 0.87
Differentiation of hemolytically active fluid-phase and cell-bound human C1q by an ant venom-derived polysaccharide. J Immunol (1980) 0.86
Contributions of C1q, bacterial lipopolysaccharide, and porins during attachment and ingestion phases of phagocytosis by murine macrophages. Infect Immun (1986) 0.86
Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy (1975) 0.85
Collagen-like complement component C1q is a membrane protein of human monocyte-derived macrophages that mediates endocytosis. J Immunol (1995) 0.85
The Cl inactivator from guinea pig serum. 3. Characterization and kinetic data of the reaction between the inactivator and EACl and EACl4. Immunochemistry (1972) 0.85
Purification and characterization of human, guinea pig and mouse C1q by fast protein liquid chromatography (FPLC). J Immunol Methods (1984) 0.84
Molecular cloning and characterization of the complementary DNA coding for the B-chain of murine Clq. FEBS Lett (1989) 0.84
Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum (1995) 0.84
MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer (2000) 0.84
HLA-DP in rheumatoid arthritis. Tissue Antigens (1988) 0.83
Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages. Immunobiology (1981) 0.83
Functional domains of the human C1q A-chain. Behring Inst Mitt (1993) 0.83
Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int (1995) 0.83
Mode of interaction of different polyanions with the first (C1,C1) the second (C2) and the fourth (C4) component of complement. IV. Activation of C1 in serum by polyanions. Immunology (1976) 0.83
Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae. Infect Immun (1984) 0.83
C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. J Biol Chem (1997) 0.83
Non-sense and missense mutations in the structural genes of complement component C1q A and C chains are linked with two different types of complete selective C1q deficiencies. J Immunol (1995) 0.83
Cognitive impact of cytotoxic agents in mice. Psychopharmacology (Berl) (2014) 0.83
Insoluble polyanions as activators of both pathways of complement. Immunology (1977) 0.83
Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest (1989) 0.83
Complement component C1 and the collectins: parallels between routes of acquired and innate immunity. Immunol Today (1998) 0.82
C1q-bearing immune complexes detected by a monoclonal antibody to human C1q in rheumatoid arthritis sera and synovial fluids. Rheumatol Int (1991) 0.82
The reconstitution of human C1, the first complement component: binding of C1r and C1s to C1q influences the C1q conformation. FEBS Lett (1981) 0.82
Inactivation of complement by L-asparaginase preparations not correlated with enzyme content. Nat New Biol (1972) 0.82
[In vitro studies on the mode of action and differences to heparin. Anticomplementary effect of a semisynthetic pentosan-polysulfo-ester]. Z Naturforsch B (1971) 0.82
Evaluation of a heterozygote test for maple syrup urine disease in leucocytes and cultured fibroblasts. Humangenetik (1971) 0.82
Complement component deficiencies and infection: C5, C8 and C3 deficiencies in three families. Eur J Pediatr (1992) 0.82
A rapid and simple ELISA for the determination of duplicate monoclonal antibodies during epitope analysis of antigens and its application to the study of C1(-)-INH. J Immunol Methods (1988) 0.82
Evidence that C1q, a subcomponent of the first component of complement, is an Fc receptor of peritoneal and alveolar macrophages. Immunobiology (1980) 0.81
Studies on the interaction of C1q, a subcomponent of the first component of complement, with porins from Salmonella minnesota incorporated into artificial membranes. FEBS Lett (1990) 0.81
Antibody-independent activation of C1, the first component of complement. Ann Immunol (Paris) (1982) 0.81
A case of selective Clq deficiency. Turk J Pediatr (1979) 0.81
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. IV. Formation of EAC42 by treatment of C2 with trypsin in the presence of EAC4. J Immunol (1972) 0.81
Antibodies to Acholeplasma laidlawii membrane lipids in normal guinea pig serum. Infect Immun (1977) 0.81
Multiple identification of a particular type of hereditary C1q deficiency in the Turkish population: review of the cases and additional genetic and functional analysis. Hum Genet (1997) 0.81
Immunohistological differential diagnosis of inflammatory colonic diseases. Histopathology (1984) 0.81
Population studies of HLA-linked SB antigens and their relative importance in primary MLC typing. Analysis of HLA-D homozygous typing cells and normal heterozygous populations. Hum Immunol (1982) 0.81
Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: parallels and differences to other known genetic C1q-defects. Immunopharmacology (1997) 0.81
Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement. J Immunol (1984) 0.81